Is PURR or LRMR more profitable?

Hyperliquid Strategies' return on equity of -56.04% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hyperliquid Strategies N/A -56.04% -52.22% Larimar Therapeutics N/A -134.14% -96.00%

Is LRMR or KALV more profitable?

Larimar Therapeutics' return on equity of -134.14% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% KalVista Pharmaceuticals N/A -341.44% -111.94%

Which has stronger earnings & valuation, LRMR or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is LRMR or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Bicara Therapeutics N/A -35.89% -33.78%

Which has higher earnings & valuation, MLTX or LRMR?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Is MLTX or LRMR more profitable?

MoonLake Immunotherapeutics' return on equity of -85.15% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -85.15% -60.52% Larimar Therapeutics N/A -134.14% -96.00%

Which has stronger valuation and earnings, LRMR or AVBP?

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is LRMR or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% ArriVent BioPharma N/A -48.98% -45.44%

Larimar Therapeutics (LRMR) Competitors

$3.10 -0.07 (-2.21%)

Closing price 04:00 PM Eastern

Extended Trading

$3.15 +0.05 (+1.61%)

As of 07:31 PM Eastern

Compare

LRMR vs. PURR, KALV, BCAX, MLTX, and AVBP

Should you buy Larimar Therapeutics stock or one of its competitors? MarketBeat compares Larimar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Larimar Therapeutics include Hyperliquid Strategies (PURR), KalVista Pharmaceuticals (KALV), Bicara Therapeutics (BCAX), MoonLake Immunotherapeutics (MLTX), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry.

How does Larimar Therapeutics compare to Hyperliquid Strategies?

Hyperliquid Strategies (NASDAQ:PURR) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Hyperliquid Strategies currently has a consensus target price of $9.25, indicating a potential upside of 3.70%. Larimar Therapeutics has a consensus target price of $15.29, indicating a potential upside of 393.09%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Hyperliquid Strategies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperliquid Strategies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

9.5% of Hyperliquid Strategies shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 8.5% of Hyperliquid Strategies shares are held by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Hyperliquid Strategies' return on equity of -56.04% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperliquid Strategies	N/A	-56.04%	-52.22%
Larimar Therapeutics	N/A	-134.14%	-96.00%

In the previous week, Hyperliquid Strategies had 3 more articles in the media than Larimar Therapeutics. MarketBeat recorded 3 mentions for Hyperliquid Strategies and 0 mentions for Larimar Therapeutics. Hyperliquid Strategies' average media sentiment score of 0.36 beat Larimar Therapeutics' score of 0.00 indicating that Hyperliquid Strategies is being referred to more favorably in the media.

Company	Overall Sentiment
Hyperliquid Strategies	Neutral
Larimar Therapeutics	Neutral

Hyperliquid Strategies has higher revenue and earnings than Larimar Therapeutics. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Hyperliquid Strategies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperliquid Strategies	$1M	1,288.49	-$16.01M	-$7.37	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Hyperliquid Strategies has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Summary

Hyperliquid Strategies beats Larimar Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Larimar Therapeutics compare to KalVista Pharmaceuticals?

Larimar Therapeutics (NASDAQ:LRMR) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Larimar Therapeutics currently has a consensus price target of $15.29, suggesting a potential upside of 393.09%. KalVista Pharmaceuticals has a consensus price target of $30.60, suggesting a potential upside of 13.38%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Larimar Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Larimar Therapeutics' return on equity of -134.14% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

In the previous week, KalVista Pharmaceuticals had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 2 mentions for KalVista Pharmaceuticals and 0 mentions for Larimar Therapeutics. KalVista Pharmaceuticals' average media sentiment score of 0.58 beat Larimar Therapeutics' score of 0.00 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Neutral
KalVista Pharmaceuticals	Positive

KalVista Pharmaceuticals has higher revenue and earnings than Larimar Therapeutics. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
KalVista Pharmaceuticals	$49.08M	29.28	-$109.52M	-$3.46	N/A

Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Summary

Larimar Therapeutics beats KalVista Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Larimar Therapeutics compare to Bicara Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Bicara Therapeutics' return on equity of -35.89% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Larimar Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.54, suggesting that its share price is 154% less volatile than the broader market.

91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Larimar Therapeutics currently has a consensus target price of $15.29, suggesting a potential upside of 393.09%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 50.61%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Larimar Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

In the previous week, Bicara Therapeutics had 8 more articles in the media than Larimar Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 0 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.18 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Larimar Therapeutics	Neutral
Bicara Therapeutics	Neutral

Summary

Larimar Therapeutics beats Bicara Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Larimar Therapeutics compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

MoonLake Immunotherapeutics currently has a consensus price target of $23.85, suggesting a potential upside of 32.48%. Larimar Therapeutics has a consensus price target of $15.29, suggesting a potential upside of 393.09%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 0 mentions for Larimar Therapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.45 beat Larimar Therapeutics' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Larimar Therapeutics	Neutral

MoonLake Immunotherapeutics' return on equity of -85.15% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Larimar Therapeutics	N/A	-134.14%	-96.00%

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Summary

MoonLake Immunotherapeutics beats Larimar Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Larimar Therapeutics compare to ArriVent BioPharma?

Larimar Therapeutics (NASDAQ:LRMR) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

In the previous week, ArriVent BioPharma had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 1 mentions for ArriVent BioPharma and 0 mentions for Larimar Therapeutics. ArriVent BioPharma's average media sentiment score of 1.32 beat Larimar Therapeutics' score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Neutral
ArriVent BioPharma	Positive

Larimar Therapeutics has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

ArriVent BioPharma's return on equity of -48.98% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
ArriVent BioPharma	N/A	-48.98%	-45.44%

ArriVent BioPharma is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Larimar Therapeutics presently has a consensus target price of $15.29, suggesting a potential upside of 393.09%. ArriVent BioPharma has a consensus target price of $43.38, suggesting a potential upside of 42.21%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Larimar Therapeutics and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$329.31M	$2.96B	$6.49B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.57%
P/E Ratio	-1.50	12.28	20.24	21.95
Price / Sales	N/A	288.30	507.57	108.00
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	3.30	3.83	10.28	6.78
Net Income	-$165.67M	$75.85M	$3.57B	$337.51M
7 Day Performance	-11.68%	-4.52%	-1.43%	-2.72%
1 Month Performance	-21.91%	-5.85%	3.27%	1.87%
1 Year Performance	15.67%	15.31%	23.37%	26.61%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	2.1174 of 5 stars	$3.10 -2.2%	$15.29 +393.1%	+18.3%	$329.31M	N/A	N/A	30
PURR Hyperliquid Strategies	1.6279 of 5 stars	$10.87 +8.8%	$9.25 -14.9%	N/A	$1.44B	$1M	N/A	N/A	Gap Up High Trading Volume
KALV KalVista Pharmaceuticals	2.6454 of 5 stars	$26.94 +0.3%	$30.60 +13.6%	+87.7%	$1.43B	$1.43M	N/A	100
BCAX Bicara Therapeutics	1.9355 of 5 stars	$20.62 -5.2%	$30.27 +46.8%	+73.9%	$1.43B	N/A	N/A	32
MLTX MoonLake Immunotherapeutics	3.6432 of 5 stars	$18.82 -1.9%	$23.85 +26.7%	-61.8%	$1.41B	N/A	N/A	2	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. PURR, KALV, BCAX, MLTX, and AVBP

How does Larimar Therapeutics compare to Hyperliquid Strategies?

Summary

How does Larimar Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Larimar Therapeutics compare to Bicara Therapeutics?

Summary

How does Larimar Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Larimar Therapeutics compare to ArriVent BioPharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. PURR, KALV, BCAX, MLTX, and AVBP

How does Larimar Therapeutics compare to Hyperliquid Strategies?

Do analysts recommend PURR or LRMR?

Do institutionals and insiders have more ownership in PURR or LRMR?

Is PURR or LRMR more profitable?

Does the media prefer PURR or LRMR?

Which has preferable valuation and earnings, PURR or LRMR?

Which has more volatility and risk, PURR or LRMR?

Summary

How does Larimar Therapeutics compare to KalVista Pharmaceuticals?

Do insiders and institutionals have more ownership in LRMR or KALV?

Do analysts recommend LRMR or KALV?

Is LRMR or KALV more profitable?

Does the media refer more to LRMR or KALV?

Which has higher valuation & earnings, LRMR or KALV?

Which has more risk & volatility, LRMR or KALV?

Summary

How does Larimar Therapeutics compare to Bicara Therapeutics?

Is LRMR or BCAX more profitable?

Which has more volatility and risk, LRMR or BCAX?

Do insiders & institutionals hold more shares of LRMR or BCAX?

Do analysts rate LRMR or BCAX?

Which has stronger earnings & valuation, LRMR or BCAX?

Does the media prefer LRMR or BCAX?

Summary

How does Larimar Therapeutics compare to MoonLake Immunotherapeutics?

Which has more risk and volatility, MLTX or LRMR?

Do analysts recommend MLTX or LRMR?

Do institutionals and insiders hold more shares of MLTX or LRMR?

Does the media favor MLTX or LRMR?

Is MLTX or LRMR more profitable?

Which has higher earnings & valuation, MLTX or LRMR?

Summary

How does Larimar Therapeutics compare to ArriVent BioPharma?

Does the media refer more to LRMR or AVBP?

Which has more risk and volatility, LRMR or AVBP?

Is LRMR or AVBP more profitable?

Which has stronger valuation and earnings, LRMR or AVBP?

Do insiders and institutionals believe in LRMR or AVBP?

Do analysts rate LRMR or AVBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools